

# Petros D Grivas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9079502/publications.pdf>

Version: 2024-02-01

214  
papers

12,604  
citations

109137

35  
h-index

28224

105  
g-index

215  
all docs

215  
docs citations

215  
times ranked

14935  
citing authors

#	ARTICLE	IF	CITATIONS
1	Urologists, Youâ€™ll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Nonâ€“muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 268-272.	2.6	1
2	Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. <i>European Urology Oncology</i> , 2022, 5, 265-267.	2.6	6
3	Association of prior local therapy and outcomes with programmedâ€“death ligandâ€“1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3
4	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 35-42.	0.9	5
5	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. <i>Cancer Investigation</i> , 2022, 40, 17-25.	0.6	2
6	Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021. <i>BJU International</i> , 2022, 129, 168-170.	1.3	3
7	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100858.	0.6	3
8	Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 114-122.	0.9	3
9	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
10	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 430-439.	2.9	15
11	TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS582-TPS582.	0.8	6
12	Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy. <i>Cancers</i> , 2022, 14, 1555.	1.7	18
13	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
14	Recurrence mechanisms of non-muscle-invasive bladder cancer â€“ a clinical perspective. <i>Nature Reviews Urology</i> , 2022, 19, 280-294.	1.9	48
15	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
16	Sarcomatoid Urothelial Carcinoma: A Population-Based Study of Clinicopathologic Characteristics and Survival Outcomes. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 139-147.	0.9	7
17	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. <i>Clinical Cancer Research</i> , 2022, 28, 1680-1689.	3.2	32
18	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2022, 128, 1194-1205.	2.0	26

#	ARTICLE	IF	CITATIONS
19	Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. <i>Future Oncology</i> , 2022, 18, 2361-2371.	1.1	4
20	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	3.2	21
21	Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. <i>Future Oncology</i> , 2022, 18, 2599-2614.	1.1	10
22	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	0.9	10
23	Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor. <i>Targeted Oncology</i> , 2022, 17, 329-341.	1.7	2
24	Real-world outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 76.e15-76.e22.	0.8	8
25	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	0.9	13
26	The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial. <i>Cancer Investigation</i> , 2021, 39, 1-9.	0.6	2
27	Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100325.	0.7	24
28	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021, 7, 107.	3.4	90
29	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 406-406.	0.8	0
30	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
31	Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 438-438.	0.8	13
32	A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS501-TPS501.	0.8	2
33	TracelT: A prospective pilot study of a temporary intravesical fiducial marker for bladder cancer radiation therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 457-457.	0.8	1
34	Approaches to immune checkpoint inhibitor (ICI) maintenance therapy in metastatic urothelial cancer (mUC): A qualitative analysis of oncology providers in the United States.. <i>Journal of Clinical Oncology</i> , 2021, 39, 407-407.	0.8	0
35	Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2021, 7, 33-42.	0.2	3
36	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. <i>Prostate</i> , 2021, 81, 418-426.	1.2	8

#	ARTICLE	IF	CITATIONS
37	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021, 39, 1-6.	0.6	4
38	Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 709-717.	0.2	7
39	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. <i>Urology</i> , 2021, 149, 154-160.	0.5	4
40	Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2021, 11, 9029.	1.6	39
41	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	5.1	225
42	Perioperative Immunotherapy in Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 131-133.	2.6	3
43	Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras. <i>JCO Oncology Practice</i> , 2021, 17, e1728-e1737.	1.4	7
44	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	15.2	56
45	The Landscape of Antibody-drug Conjugates in Urothelial Cancer. <i>Advances in Oncology</i> , 2021, 1, 273-282.	0.1	0
46	Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. <i>Bladder Cancer</i> , 2021, 7, 143-148.	0.2	2
47	Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). <i>BMC Cancer</i> , 2021, 21, 593.	1.1	34
48	First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4508-4508.	0.8	21
49	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 97, 102187.	3.4	31
50	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
51	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1033-1033.	0.7	23
52	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
53	Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. <i>Future Oncology</i> , 2021, 17, 2545-2558.	1.1	39
54	Chemoimmunotherapy in urothelial cancer: concurrent or sequential?. <i>Lancet Oncology</i> , The, 2021, 22, 894-896.	5.1	4

#	ARTICLE	IF	CITATIONS
55	Care without a compass: Including patients with cancer in COVID-19 studies. <i>Cancer Cell</i> , 2021, 39, 895-896.	7.7	14
56	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	2.0	5
57	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
58	Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	3
59	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2474-2485.	0.8	250
60	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 896-904.	2.3	13
61	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
62	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
63	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e1-496.e8.	0.8	1
64	Reply to T. Powles et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01673.	0.8	0
65	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 425-433.	0.9	15
66	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 732.e9-732.e16.	0.8	6
67	Clinical Trials in Metastatic Urothelial Carcinoma. , 2021, , 365-372.		0
68	Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review. <i>Translational Andrology and Urology</i> , 2021, 10, 4022-4035.	0.6	3
69	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1339-1346.	1.6	58
70	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1415-1424.	2.3	10
71	816-...Selective immune suppression using interleukin-6 blockade in immune related adverse events. , 2021, 9, A853-A853.		1
72	630-...Oncologists' perspectives on evolution of first-line immune checkpoint inhibitor maintenance therapy in management of advanced urothelial carcinoma in the US. , 2021, 9, A660-A660.		0

#	ARTICLE	IF	CITATIONS
73	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021, 27, 2200-2211.	15.2	65
74	The utility of next generation sequencing in advanced urothelial carcinoma. <i>European Urology Focus</i> , 2020, 6, 41-44.	1.6	18
75	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
76	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020, 3, 695-699.	2.6	30
77	Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e266-e276.	0.9	12
78	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	0.8	15
79	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
80	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.	0.2	16
81	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	0.9	18
82	Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications. <i>Bladder Cancer</i> , 2020, 6, 107-122.	0.2	17
83	Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. <i>Cancer</i> , 2020, 126, 4446-4450.	2.0	7
84	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
85	Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <i>Targeted Oncology</i> , 2020, 15, 541-548.	1.7	6
86	Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer. <i>Cancer Medicine</i> , 2020, 9, 9365-9372.	1.3	16
87	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.	13.9	802
88	Comparison of Health Care Utilization at the End of Life Among Patients With Cancer in Alberta, Canada, Versus Washington State. <i>JCO Oncology Practice</i> , 2020, 16, e1543-e1552.	1.4	6
89	Adjuvant Treatment of Residual Disease Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2020, 6, 525-535.	0.2	0
90	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26

#	ARTICLE	IF	CITATIONS
91	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	6.3	1,395
92	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
93	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2658-2666.	0.8	186
94	Converging Roads to Early Bladder Cancer. <i>European Urology</i> , 2020, 78, 127-130.	0.9	5
95	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 211-220.	1.7	14
96	Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100179.	0.7	4
97	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
98	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	0.9	41
99	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 500-508.	0.9	10
100	Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 3671-3690.	2.4	20
101	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 332-339.e2.	0.9	5
102	Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. <i>European Urology Oncology</i> , 2020, 3, 351-359.	2.6	31
103	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
104	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020, 204, 1173-1179.	0.2	47
105	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5000-5000.	0.8	43
106	Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5027-5027.	0.8	14
107	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA1-LBA1.	0.8	64
108	Comprehensive genomic profiling (CGP) in post-systemic treatment (Post) metastatic sites (MET) and pretreatment (Pre) primary tumors (PT) of metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 175-175.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial.. Journal of Clinical Oncology, 2020, 38, 440-440.	0.8	21
110	Real-world prognostic model for overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 447-447.	0.8	0
111	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. Journal of Clinical Oncology, 2020, 38, 426-426.	0.8	0
112	The emerging target <i>KRAS</i> G12C in genitourinary malignancies.. Journal of Clinical Oncology, 2020, 38, 434-434.	0.8	1
113	<i>NF2</i> mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 726-726.	0.8	6
114	Metastatic renal cell carcinoma (mRCC) in young patients: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2020, 38, 727-727.	0.8	0
115	Sarcomatoid urothelial carcinoma (SUC): A single-institution experience of oncologic outcomes and recurrence patterns.. Journal of Clinical Oncology, 2020, 38, 465-465.	0.8	1
116	Noninvasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?. BJU International, 2019, 124, 361-362.	1.3	0
117	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight, 2019, 4, .	2.3	30
118	Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy. Current Treatment Options in Oncology, 2019, 20, 67.	1.3	12
119	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Targeted Oncology, 2019, 14, 505-525.	1.7	40
120	SIU's ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 61-83.	1.2	40
121	Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. European Urology Oncology, 2019, 2, 565-571.	2.6	20
122	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 284-300.	1.8	14
123	Precision therapy in advanced urothelial cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 81-93.	0.4	4
124	Systematic Review: Targeting HER2 in Bladder Cancer. Bladder Cancer, 2019, 5, 1-12.	0.2	34
125	Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clinical Cancer Research, 2019, 25, 3908-3920.	3.2	71
126	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 2019, 17, 177-182.	0.9	11

#	ARTICLE	IF	CITATIONS
127	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. <i>Bladder Cancer</i> , 2019, 5, 289-298.	0.2	7
128	The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma. <i>Oncologist</i> , 2019, 24, 580-583.	1.9	0
129	Capturing recurrence in urothelial carcinoma: "more than meets the eye". <i>Translational Andrology and Urology</i> , 2019, 8, S524-S527.	0.6	0
130	The Cancer Immunogram: A Pledge for a Comprehensive Biomarker Approach for Personalized Immunotherapy in Urothelial Cancer. <i>European Urology</i> , 2019, 75, 445-447.	0.9	12
131	DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?. <i>Clinical Cancer Research</i> , 2019, 25, 907-909.	3.2	11
132	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	2.0	38
133	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. <i>Cancer</i> , 2019, 125, 533-540.	2.0	38
134	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	3.2	48
135	Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of care (SOC) regimens.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4532-4532.	0.8	1
136	KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)" Updated response and survival results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4546-4546.	0.8	19
137	5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4552-4552.	0.8	3
138	Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4581-4581.	0.8	6
139	Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16007-e16007.	0.8	6
140	TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3153-TPS3153.	0.8	6
141	FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3157-TPS3157.	0.8	18
142	Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 350-350.	0.8	103
143	Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 363-363.	0.8	1
144	Association between stromal/TGF- $\beta$ 2/EMT gene expression signature and response to pembrolizumab monotherapy in cisplatin-ineligible patients with locally advanced (unresectable) or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 433-433.	0.8	7

#	ARTICLE	IF	CITATIONS
145	Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2019, 37, 451-451.	0.8	24
146	TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2019, 37, TPS495-TPS495.	0.8	3
147	Education and informed decision making for prostate cancer screening in a high risk African American community. Integrative Clinical Medicine, 2019, 3, .	0.1	2
148	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 750-757.	2.3	86
149	The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. Translational Cancer Research, 2019, 8, S130-S132.	0.4	1
150	Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype.. Journal of Clinical Oncology, 2019, 37, e16016-e16016.	0.8	0
151	Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients.. Journal of Clinical Oncology, 2019, 37, 5032-5032.	0.8	0
152	Circulating cell-free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC).. Journal of Clinical Oncology, 2019, 37, 4523-4523.	0.8	0
153	Bladder Cancer Multidisciplinary Clinic (BCMC) model: Impact on imaging, pathology and treatment recommendations.. Journal of Clinical Oncology, 2019, 37, 4537-4537.	0.8	0
154	Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY).. Journal of Clinical Oncology, 2019, 37, 4553-4553.	0.8	0
155	Association of cell-free DNA (cfDNA) levels with myeloid-derived suppressor cells (MDSC) levels in blood of patients (pts) with muscle invasive (MI) and metastatic (met) bladder cancer (BC).. Journal of Clinical Oncology, 2019, 37, 4528-4528.	0.8	1
156	Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).. Journal of Clinical Oncology, 2019, 37, 5081-5081.	0.8	0
157	Treatment sequencing of anti-PD-1/PD-L1 and carboplatin (carbo)-based chemotherapy (chemo) in cisplatin-ineligible patients (pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2019, 37, 4541-4541.	0.8	0
158	Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.. Journal of Clinical Oncology, 2019, 37, 4525-4525.	0.8	1
159	Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response.. Journal of Clinical Oncology, 2019, 37, e14032-e14032.	0.8	0
160	First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2019, 37, e16024-e16024.	0.8	0
161	PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).. Journal of Clinical Oncology, 2019, 37, TPS4594-TPS4594.	0.8	3
162	The importance of not only living longer but also better in the setting of advanced urothelial cancer. Annals of Translational Medicine, 2019, 7, S187-S187.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Intensity of end-of-life (EOL) cancer care in Western Washington (WA) versus Alberta (AB), Canada (CA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 89-89.	0.8	0
164	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018, 124, 2115-2124.	2.0	79
165	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 423-431.	0.8	16
166	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018, 13, 353-361.	1.7	14
167	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 405-412.	0.8	40
168	Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 48.	1.8	40
169	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e879-e892.	0.9	25
170	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e751-e760.	0.9	17
171	Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map Analysis. <i>Urology Practice</i> , 2018, 5, 383-390.	0.2	3
172	Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. <i>European Urology</i> , 2018, 73, 541-542.	0.9	9
173	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e437-e442.	0.9	23
174	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 413-422.	0.8	32
175	Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. <i>Translational Andrology and Urology</i> , 2018, 7, 504-507.	0.6	3
176	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	6
177	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 599-609.	1.7	22
178	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1237-e1242.	0.9	34
179	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	2.9	39
180	Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2018, 23, 1494-1499.	1.9	15

#	ARTICLE	IF	CITATIONS
181	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1019-1040.	0.9	55
182	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. <i>European Urology</i> , 2018, 74, 741-753.	0.9	54
183	Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1511-1511.	0.8	5
184	First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16517-e16517.	0.8	3
185	Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 439-439.	0.8	4
186	<i>ATM/RB1</i> mutations predict shorter overall survival in urothelial cancer. <i>Oncotarget</i> , 2018, 9, 16891-16898.	0.8	28
187	Emerging biomarkers and targeted therapies in urothelial carcinoma. <i>Annals of Translational Medicine</i> , 2018, 6, 250-250.	0.7	33
188	Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center. <i>Journal of Cancer Education</i> , 2017, 32, 871-877.	0.6	6
189	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	6.3	1,728
190	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2017, 18, 1483-1492.	5.1	1,034
191	Challenges faced when identifying patients for combination immunotherapy. <i>Future Oncology</i> , 2017, 13, 1607-1618.	1.1	10
192	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 23-30.e2.	0.9	50
193	Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4502-4502.	0.8	49
194	Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4537-4537.	0.8	4
195	Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16005-e16005.	0.8	1
196	Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 334-334.	0.8	8
197	Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 617-623.	0.4	12
198	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	6.3	3,077

#	ARTICLE	IF	CITATIONS
199	Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2016, 34, 695-701.	1.2	3
200	PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).. <i>Journal of Clinical Oncology</i> , 2016, 34, 104-104.	0.8	32
201	PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16023-e16023.	0.8	4
202	Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. <i>Oncotarget</i> , 2016, 7, 52442-52449.	0.8	6
203	Immunobiology and immunotherapy in genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2016, 4, 270-270.	0.7	14
204	Contemporary Systemic Therapy for Urologic Malignancies in Geriatric Patients. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 645-665.	1.0	1
205	The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. <i>Seminars in Cancer Biology</i> , 2015, 35, 125-132.	4.3	20
206	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014, 120, 2684-2693.	2.0	105
207	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014, 120, 692-701.	2.0	91
208	Transcriptional corepressors in cancer. <i>Cancer</i> , 2013, 119, 1120-1128.	2.0	10
209	A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder. <i>Urology</i> , 2013, 82, 111-117.	0.5	30
210	Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 82-93.	2.0	22
211	Radium-223: a new treatment option for bone-metastatic CRPC. <i>Nature Reviews Urology</i> , 2013, 10, 630-631.	1.9	1
212	Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer. <i>Molecular Medicine</i> , 2013, 19, 367-376.	1.9	24
213	Urethral Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1291-1314.	0.9	28
214	Urothelial carcinomas: a focus on human epidermal receptors signaling. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 362-73.	0.0	27